https://www.selleckchem.com/pr....oducts/shp099-dihydr
2%] and Class B = 19 [26.8%]). Sixty patients completed the study (mean age 61.7 ± 8.8 years, males 40 [66.6%], and CTP Class A = 45 [75.0%] and Class-B = 15 [25.0%]). Two patients dropped out due to adverse events. Nine patients were lost to follow up. Patients given melatonin had a significantly lower PSQI and ESS compared to both pretreatment (   0.001) and postplacebo scores (   0.001). Incidence of adverse events was similar (two each of abdominal pain, one each of headache, one each of dizziness) in both gro

https://www.selleckchem.com/pr....oducts/Nafamostat-me
The pharmaceutical industry faces, as many other public and private sectors, a significant deficit in trust (medication considered too expensive, not always readily available, even if it is deemed essential, lack of financial transparency). Moreover, we are more than very surprised by the lack of efficiency (colossal investments, compared to the modest final output). Not a single human activity sector can afford the luxury of such a situation. In these moments of doubts, industrial leaders are pushed to reinvent the whole se